secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001104659-23-116285
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Therapeutics receives Nasdaq bid price deficiency notice; faces dual listing compliance issues
--------------------------------------------------------------------------------

- Common stock failed minimum $1.00 closing bid for 30 consecutive days through Nov 6, 2023.
- Company has 180 calendar days, until May 6, 2024, to regain bid price compliance.
- Also under stockholders' equity deficiency; Nasdaq panel granted exception until Jan 22, 2024 to demonstrate compliance.
- Company may consider a reverse stock split to regain compliance with bid price rule.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923116285/0001104659-23-116285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923116285/tm2330305d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer